Silo Pharma Increases Authorized Common Shares to 250M; Board Re‑Elected

What Happened

• Silo Pharma, Inc. (SILO) filed an 8-K on August 17, 2026 reporting that on August 14, 2026 shareholders approved a Certificate of Amendment to increase the company’s authorized common stock from 6,666,667 shares to 250,000,000 shares (common stock, $0.0001 par value). The Certificate of Amendment was filed on August 14, 2026.
• At the company’s annual meeting on August 14, 2026, shareholders also re-elected four directors and ratified the appointment of Salberg & Company, P.A. as the company’s independent registered public accounting firm for fiscal 2026.

Key Details

• Authorized shares change: increased from 6,666,667 to 250,000,000 common shares; Certificate of Amendment filed August 14, 2026.
• Meeting quorum: 697,308 shares represented in person or by proxy.
• Director elections (votes For / Withhold / Broker Non-Votes):
  • Eric Weisblum: 359,287 For, 7,489 Withhold, 330,532 Broker Non‑Votes
  • Wayne D. Linsley: 359,335 For, 7,441 Withhold, 330,532 Broker Non‑Votes
  • Dr. Kevin Muñoz: 359,324 For, 7,452 Withhold, 330,532 Broker Non‑Votes
  • Dr. Jeff Pavell: 359,383 For, 7,393 Withhold, 330,532 Broker Non‑Votes
• Auditor ratification: Salberg & Company, P.A. ratified — 690,743 For, 2,571 Against, 3,994 Abstain.
• Vote on increasing authorized shares: 498,224 For, 190,599 Against, 8,485 Abstain.
• Adjournment authorization approved: 556,797 For, 131,873 Against, 8,638 Abstain.

Why It Matters

• Increasing authorized common shares gives the company flexibility to issue additional shares for financing, equity compensation, or other corporate purposes; investors should note potential future dilution if new shares are issued.
• Re-election of the current board and ratification of the auditor maintain continuity of management and external oversight through at least the next annual meeting and fiscal year 2026 audit.